China Medical System Holdings (China Medical System Holdings) Cash-to-Debt : 4.72 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is China Medical System Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. China Medical System Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.72.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, China Medical System Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for China Medical System Holdings's Cash-to-Debt or its related term are showing as below:

CHSYF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3 Med: 1.51 Max: 4.72
Current: 4.72

During the past 13 years, China Medical System Holdings's highest Cash to Debt Ratio was 4.72. The lowest was 0.30. And the median was 1.51.

CHSYF's Cash-to-Debt is ranked better than
70.42% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs CHSYF: 4.72

China Medical System Holdings Cash-to-Debt Historical Data

The historical data trend for China Medical System Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

China Medical System Holdings Cash-to-Debt Chart

China Medical System Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.92

4.45

2.55

3.24

4.72

China Medical System Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.55	2.91	3.24	4.60	4.72

Competitive Comparison of China Medical System Holdings's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Medical System Holdings's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where China Medical System Holdings's Cash-to-Debt falls into.

China Medical System Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

China Medical System Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	860.384	/	(179.976	+	2.335)
	=	4.72

China Medical System Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	860.384	/	(179.976	+	2.335)
	=	4.72

China Medical System Holdings (OTCPK:CHSYF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

China Medical System Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of China Medical System Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

China Medical System Holdings (China Medical System Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Medical System Holdings Ltd (OTCPK:CHSYF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

00867:Hong Kong 2M7C:Germany

Address

510 King’s Road, Unit 2106, 21st Floor, North Point, Island Place Tower, Hong Kong, HKG

Website

http://www.cms.net.cn

China Medical System Holdings Ltd is active in the healthcare segment. It is one of the leading China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil; Salofalk; Combizym; Ganfule Capsules; Xidakang; Hirudoid; and others. Geographically, it derives revenue from China.

China Medical System Holdings (China Medical System Holdings) Headlines

From GuruFocus

China Medical System Holdings Ltd (CHSYF): A Deep Dive into its Upcoming Dividend

By GuruFocus Research • 09-11-2023

Gelonghui Reports CMS' Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets

By ACN Newswire ACN Newswire • 12-20-2022

China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug

By ACN Newswire • 08-27-2023